PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Pharming Group NV (PHAR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US71716E1055

Sector

Healthcare

IPO Date

Dec 23, 2020

Highlights

Market Cap

$577.96M

EPS (TTM)

-$0.27

Total Revenue (TTM)

$204.55M

Gross Profit (TTM)

$181.35M

EBITDA (TTM)

-$6.66M

Year Range

$6.65 - $12.20

Target Price

$27.00

Short %

0.01%

Short Ratio

1.36

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
PHAR vs. TRMD
Popular comparisons:
PHAR vs. TRMD

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Pharming Group NV, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%30.00%SeptemberOctoberNovemberDecember2025February
4.19%
9.31%
PHAR (Pharming Group NV)
Benchmark (^GSPC)

Returns By Period

Pharming Group NV had a return of -15.35% year-to-date (YTD) and -22.62% in the last 12 months.


PHAR

YTD

-15.35%

1M

-14.89%

6M

4.19%

1Y

-22.62%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of PHAR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-12.97%-15.35%
202411.55%-10.20%-5.33%-9.87%-6.35%-8.74%-0.24%-7.68%7.28%8.00%-17.51%36.94%-11.94%
202321.21%-8.60%10.47%-17.63%7.91%-2.92%3.00%4.96%-9.49%4.04%-2.61%-1.04%3.63%
20220.37%3.09%-2.81%-7.65%-2.07%7.75%-13.06%59.01%-18.74%-1.52%28.59%-11.48%23.38%
2021-5.89%-4.62%-5.94%0.04%-5.34%-7.24%0.53%-2.47%-14.03%-5.26%-10.67%11.19%-41.16%
2020-9.01%-9.01%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PHAR is 28, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PHAR is 2828
Overall Rank
The Sharpe Ratio Rank of PHAR is 2828
Sharpe Ratio Rank
The Sortino Ratio Rank of PHAR is 3030
Sortino Ratio Rank
The Omega Ratio Rank of PHAR is 3030
Omega Ratio Rank
The Calmar Ratio Rank of PHAR is 2323
Calmar Ratio Rank
The Martin Ratio Rank of PHAR is 2626
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Pharming Group NV (PHAR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for PHAR, currently valued at -0.34, compared to the broader market-2.000.002.00-0.341.74
The chart of Sortino ratio for PHAR, currently valued at -0.08, compared to the broader market-4.00-2.000.002.004.006.00-0.082.35
The chart of Omega ratio for PHAR, currently valued at 0.99, compared to the broader market0.501.001.502.000.991.32
The chart of Calmar ratio for PHAR, currently valued at -0.38, compared to the broader market0.002.004.006.00-0.382.61
The chart of Martin ratio for PHAR, currently valued at -0.87, compared to the broader market0.0010.0020.0030.00-0.8710.66
PHAR
^GSPC

The current Pharming Group NV Sharpe ratio is -0.34. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Pharming Group NV with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.34
1.74
PHAR (Pharming Group NV)
Benchmark (^GSPC)

Dividends

Dividend History


Pharming Group NV doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-48.98%
0
PHAR (Pharming Group NV)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Pharming Group NV. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pharming Group NV was 60.45%, occurring on Jun 16, 2022. The portfolio has not yet recovered.

The current Pharming Group NV drawdown is 48.98%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-60.45%Dec 24, 2020372Jun 16, 2022

Volatility

Volatility Chart

The current Pharming Group NV volatility is 17.02%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
17.02%
3.07%
PHAR (Pharming Group NV)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Pharming Group NV over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Pharming Group NV.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab